Innovotech

Innovotech Net Debt/Equity

The Net Debt to Equity Ratio of Innovotech (IOT.V) as of Nov 20, 2026 is 0.04. In the previous year, Net Debt to Equity Ratio was 0.03 — a change of 43.87% (higher).

Net Debt/Equity

0.04

YoY

43.87%

Last updated:

Net Debt to Equity Ratio of Innovotech is 2025 0.04 . Net Debt to Equity Ratio of Innovotech was 2024 0.03 . It decreases by 43.87% higher compared to the previous year.

The Innovotech Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2014
-0.15 CAD
Jan 1, 2015
-0.11 CAD
Jan 1, 2016
-0.10 CAD
Jan 1, 2017
0.58 CAD
Jan 1, 2018
1.07 CAD
Jan 1, 2019
1.02 CAD
Jan 1, 2020
0.03 CAD
Jan 1, 2025
0.04 CAD
The Innovotech Net Debt/Equity history
YEARNet Debt/EquityYoY
0.04+43.87%
0.03-96.96%
1.02-4.71%
1.07+84.94%
0.58-663.90%
-0.10-8.54%
-0.11-23.66%
-0.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innovotech Stock analysis

What does Innovotech do? Innovotech Inc. generates revenue through the sale of proprietary assay kits, including MBEC Assay Kits, Order Biofilm Assays, and Coated MBEC Assay Lids, which are used in microbial biofilm research. The company also provides contract research services such as Antimicrobial Contract Research, Antimicrobial and Anti-Biofilm Agents testing (MIC and MBEC), and Customized Antimicrobial Testing (BEST Assay Testing and Implanted Medical Device Testing). Its antimicrobial silver products, AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products, are sold to customers in agricultural and medical sectors. The firm targets research institutions, agricultural producers, and medical device manufacturers seeking biofilm and antimicrobial testing solutions. Innovotech's intellectual property portfolio supports its contract research services, which include testing for antimicrobial agents and materials under standards like TM100, ISO 22196, and USP 51. The company’s Biofilm Publications and SEM Library serve as additional resources for clients engaged in biofilm research. Its product offerings are tailored to sectors requiring microbial biofilm analysis, such as crop protection and medical device development, with AgreGuard-1 and InnovoSIL products specifically addressing antimicrobial needs in agriculture and medical applications. The company monetizes its proprietary technology through direct sales of assay kits and antimicrobial silver products, while contract research services provide recurring revenue streams. Clients include research organizations conducting biofilm studies, agricultural businesses using AgreGuard-1 for crop protection, and medical device manufacturers utilizing InnovoSIL for antimicrobial properties. Innovotech’s focus on specialized testing methodologies and branded products ensures consistent demand from niche markets requiring precise biofilm and antimicrobial evaluation. Innovotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innovotech stock

Net Debt to Equity Ratio of Innovotech is 0.04 in 2025.

Net Debt to Equity Ratio of Innovotech changed from 0.03 to 0.04, representing a 43.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Innovotech since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Innovotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Innovotech

All Key Metrics — Innovotech